Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

British Journal of Cancer

Volumn 101, Issue 10, 2009, Pages 1699-1708

  Konecny, G E ^a,b   Glas, R ^a   Dering, J ^a   Manivong, K ^a   Qi, J ^a   Finn, R S ^a   Yang, G R ^a   Hong, K L ^a   Ginther, C ^a   Winterhoff, B ^b   Gao, G ^c   Brugge, J ^c   Slamon, D J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dasatinib; Eph2A; FAK; Ovarian cancer; Src; UPA

Indexed keywords

ANNEXIN; CARBOPLATIN; CAVEOLIN 1; CAVEOLIN 2; DASATINIB; EPHRIN RECEPTOR A2; FOCAL ADHESION KINASE; MOESIN; MOLECULAR MARKER; PACLITAXEL; PROTEIN KINASE LYN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FLOW CYTOMETRY; FOCAL ADHESION KINASE 1; GENE EXPRESSION PROFILING; HUMANS; INHIBITORY CONCENTRATION 50; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-YES; PYRIMIDINES; RECEPTOR, EPHA2; SRC-FAMILY KINASES; THIAZOLES;

EID: 70449533848     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605381     Document Type: Article

References (48)

1. Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T (2008) Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br J Cancer 98: 845-851
2. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC (2007) Current management strategies for ovarian cancer. Mayo Clin Proc 82(6): 751-770
3. Bailey KM, Liu J (2008) Caveolin-1-up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. J Biol Chem 283(20): 13714-13724
4. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U, Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25(9): 1035-1044
5. Budde RJ, Ke S, Levin VA (1994) Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 14(3): 171-175
6. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25(5): 517-525
7. Eustace AJ, Crown J, Clynes M, O'Donovan N (2008) Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 6: 53
8. Fincham VJ, Frame MC (1998) The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. EMBO J 17(1): 81-92
9. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal type/ 'triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3): 319-326
10. Fu XD, Giretti MS, Baldacci C, Garibaldi S, Flamini M, Sanchez AM, Gadducci A, Genazzani AR, Simoncini T (2008) Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS ONE 3(7): e2790
11. Glynn SA, Gammell P, Heenan M, O0Connor R, Liang Y, Keenan J, Clynes M (2004) A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br J Cancer 91: 1800-1807
12. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67(5): 2226-2238 (Pubitemid 46424242)
13. Ireton RC, Davis MA, van Hengel J, Mariner DJ, Barnes K, Thoreson MA, Anastasiadis PZ, Matrisian L, Bundy LM, Sealy L, Gilbert B, van Roy F, Reynolds AB (2002) A novel role for p120 catenin in E-cadherin function. J Cell Biol 159(3): 465-476
14. Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11(19): 6924-6932
15. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS (2007) The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96: 1083-1091
16. Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM, Mendel DB (2003) Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and-independent growth of human tumor cells. Mol Cancer Ther 2(5): 461-469
17. Landgren E, Blume-Jensen P, Courtneidge SA, Claesson-Welsh L (1995) Fibroblast growth factor receptor-1-regulation of Src family kinases. Oncogene 10(10): 2027-2035
18. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydro-xyethyl)-piperazin-1-yl) 2-methylpyrimidin-4-ylamino)thiazole-5-car-boxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27): 6658-6661
19. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman TJ (1997) Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15(25): 3083-3090 (Pubitemid 28043487)
20. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 104(13): 5563-5568
21. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP (1995) Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375(6532): 577-581
22. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ (1994) Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 14(1): 735-743
23. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R (2005) Action of the Src family kinase inhibitor, das-atinib (BMS-354825), on human prostate cancer cells. Cancer Res 65(20): 9185-9189
24. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96(10): 739-749
25. Rahimi N, Hung W, Tremblay E, Saulnier R, Elliott B (1998) c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J Biol Chem 273(50): 33714-33721
26. Reynolds AB, Roczniak-Ferguson A (2004) Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene 23(48): 7947-7956
27. Rosenblatt J (2008) Mitosis: moesin and the importance of being round. Curr Biol 18(7): 292-293
28. Schaller MD (2001) Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 1540(1): 1-21
29. Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW (2004) Integrin-mediated action of insulin like growth factor binding protein-2-in tumor cells. J Mol Endocrinol 32(3): 859-868
30. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 5(12): 3014-3022
31. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66(11): 5542-5548
32. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, Hendrix MJ (2004) Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 165(4): 1087-1095
33. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4): 337-358
34. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541 (Pubitemid 43882349)
35. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10: 5145-5150
36. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13: 513-609
37. Tice DA, Biscardi JS, Nickles AL, Parsons SJ (1999) Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96(4): 1415-1420
38. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM (2007) Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7): 1962-1972
39. Tyler T (2009) Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. Ann Pharmacother 43(5): 920-927
40. Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R (2003) Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett 543(1-3): 76-80
41. Wang GK, Hu L, Fuller GN, Zhang W (2006) An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 281(20): 14085-14091
42. Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M, Chen T, Bleickardt E, Nicaise C, Shah N (2008) Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol 26(May 20 suppl; abstract no. 3590
43. Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, Huang F (2007) Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 8(11): R255
44. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE (2003) Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88(1): 73-79
45. Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM (2006) The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol 102: 15-21
46. Wykosky J, Debinski W (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6(12): 1795-1806
47. Yamada S, Pokutta S, Drees F, Weis WI, Nelson WJ (2005) Deconstructing the cadherin-catenin-actin complex. Cell 123(5): 889-901
48. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4(6): 470-480